During the past 3 years, the average EPS without NRIGrowth Rate was 78.90% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.
During the past 5 years, Sonnet BioTherapeutics Holdings's highest 3-Year average EPS without NRI Growth Rate was 78.90% per year. The lowest was 18.80% per year. And the median was 48.85% per year.
Sonnet BioTherapeutics Holdings EPS (Diluted) Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Sonnet BioTherapeutics Holdings's EPS (Diluted)
For the Biotechnology subindustry, Sonnet BioTherapeutics Holdings's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sonnet BioTherapeutics Holdings's PE Ratio Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Sonnet BioTherapeutics Holdings's PE Ratio distribution charts can be found below:
* The bar in red indicates where Sonnet BioTherapeutics Holdings's PE Ratio falls into.
EPS (Diluted) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Diluted EPS takes into account all of the outstanding dilutive securities that could potentially be exercised (such as stock options and convertible preferred stock) and shows how such an action would impact earnings per share.
EPS (Diluted) for the trailing twelve months (TTM) ended in Jun. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-24.32
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.
Be Aware
Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.
If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.
Sonnet BioTherapeutics Holdings EPS (Diluted) Related Terms
Thank you for viewing the detailed overview of Sonnet BioTherapeutics Holdings's EPS (Diluted) provided by GuruFocus.com. Please click on the following links to see related term pages.
Sonnet BioTherapeutics Holdings Business Description
Sonnet BioTherapeutics Holdings Inc is a clinical-stage biotechnology company. The company has developed FHAB (Fully Human Albumin Binding) technology which is well suited for drug development across a range of human disease areas, including in oncology, autoimmune, pathogenic, inflammatory, and hematological conditions. The firm's pipeline products include SON-080 (low-dose IL-6), SON-1210 (IL15- FHAB-IL12), SON-1010 (IL12-FHAB), and others.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
SONN has been successfully added to your 